SMARCA4 and non-small cell lung carcinoma: Furthermore, palbociclib treatment in SMARCA4-deficient NSCLC cells induces strong G1 cell cycle arrest (Fig. 1e, f) but not cell death as indicated by the lack of Annexin V staining (Supplementary Fig. 5).